A key molecular mechanism of endocrine resistance in HR+ breast cancer involves dysregulation of the cyclin D-CDK4/6-Rb signaling axis, which controls the transition from the G1 to S phase of the cell cycle. This evidence concerns the gene CDK4 and breast carcinoma.